Results 71 to 80 of about 1,610,894 (277)

Management of Metastatic Pulmonary Spindle Cell Carcinoma With Upfront Pembrolizumab-Chemotherapy and Subsequent Ipilimumab–Nivolumab Salvage Therapy: A Case Report

open access: yesCase Reports in Oncological Medicine
Sarcomatoid carcinoma is a heterogeneous and rare subset of non–small cell lung cancers (NSCLCs), comprising pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, pulmonary blastoma, and carcinosarcoma.
Raheel Siddiqui   +2 more
doaj   +1 more source

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma

open access: yesJournal for ImmunoTherapy of Cancer, 2020
Background Neuroblastoma (NB) is a childhood cancer for which new treatment options are needed. The success of immune checkpoint blockade in the treatment of adult solid tumors has prompted the exploration of immunotherapy in NB; however, clinical ...
Marjan Rafat   +9 more
doaj   +1 more source

Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy

open access: yesJournal for ImmunoTherapy of Cancer
Background Programmed death-ligand 1 (PD-L1)-targeted radiopharmaceutical therapy (RPT) combined with immune checkpoint blockade (ICB) represents a promising combinatorial treatment because of the “magic” bystander and abscopal effects of RPT.
Siqi Zhang   +15 more
openaire   +2 more sources

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

Assessment of Blocking Interleukin-17 Antibodies in Tumor Immunotherapy with Checkpoint Inhibitors or Tumor-Specific T Cells in Implanted and UVB-Induced Cancers

open access: yesBiomedicines
Background: Immune checkpoint inhibitors and adoptive T-cell therapies have substantially improved cancer treatment outcomes, but their use is often limited by immune-related toxicities, including cytokine release syndrome.
Yuko Tsuruta   +4 more
doaj   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

open access: yesMolecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi   +2 more
wiley   +1 more source

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

open access: yesJournal of Nanobiotechnology
The combination of immune checkpoint inhibitors and immunogenic cell death (ICD) inducers has become a promising strategy for the treatment of various cancers.
Wenqi Shen   +8 more
doaj   +1 more source

DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation

open access: yeseLife
Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in
Nicholas J Mullen   +15 more
doaj   +1 more source

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer

open access: yesnpj Breast Cancer, 2021
We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors.
Dobrin Draganov   +5 more
doaj   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

open access: yesFEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy